¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º y7iHB k"^:  
$mH'%YDIl  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ qFqK. u  
 l,}^<P]  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) VLLE0W _]  
\=3fO(  
1. ICAM-1 J5i$D0K[  
S"}G/lBx.  
2. interleukin 12(IL-12) =Gl6~lJ{_  
**RW 9FU  
3. tumor infiltrating lymphocyte ,WvCslZ  
Cob<N '.  
4. TCR/CD3 complex h'QEwW  
p3e_:5k  
5. hematopoietin receptor family c8R#=^ DD  
!)!<. x  
6. individual idiotype(IdI) [ X7LV  
Cp`>dtCd  
7. integrin I;=HXL  
Zze(Ik  
8. colony-stimulatory factor (CSF) $qvk9 B0E  
:o2^?k8k&#  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© |FR'?y1  
t;^NgkP{$  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? -5&|"YYjr{  
z?b[ 6DLV;  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ J2va Kl  
31FQ=(K  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠc:$W5j('Z  
8J5{}4s\f  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ +W xZB  
\W;+@w|c  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) =m+'orJ1  
/q3]AVV  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ #]vy`rv  
)q+Qtz6D  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) cb9ndZ)v.  
L_k'r\L  
3. immunoglobulin superfamily (IgSF) O<:"Irq\qr  
 GD]yP..  
4. selectin !8z,}HUdK  
BB>R=kt  
5. anti-idiotypic antibody (¦ÁId) 0U d.u  
R Cgn\  
6. major histocompatibility complex(MHC) ~boTh   
Ki8]+W37  
7. immunotolerance 5Az4<  
U|NVDuo{{x  
8. biological reponse modifier(BRM) IpRdGT02  
~S$\ PG4  
9. immune reponse gene (Ir gene) FA+'E  
}H> }v/  
10. reshaped antibody (or reconstituted antibody) -=+@/@nV  
<z=d5g{n  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© oa K&!$S]  
K).Gj2 $  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ yLDv/r  
:'F7^ N3;H  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? -q8R'?z[  
gaIN]9wLm  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ kt0ma/QpP  
H/v|H}d;  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? "s6\l~+9l  
I|SQhbi  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ .}O _5b(  
5g-AB`6T  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? WqHsf1? N  
mHYR?  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ ):c)$$dn  
e[:i`J 2  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ k v>rv37u  
SdJGhU  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? DMcH, _(  
JJ+A+sfdk  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 7SyysH<H  
/ta5d;@  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: GlPd)m`  
`/4 R$E{  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: :Nt_LsH  
L6ifT`;T  
ÃâÒßѧ e0nr dM[i  
dP7nR1GS  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© @N%/v*  
b;O@|HK&~  
1. CD8 B'kV.3t  
=rB=! ;  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) W7 .Y`u[  
wyVQV8+&>  
3. immunoglobulin fold(Ig fold) 0Gr^#`  
?cH,!2  
4. cadherin (Ca-dependent cell adhesion moleculers) mx ]a@tu  
i"HENJyCb  
5. idiotype-anti-idiotypic antibody immune network theory 5J1q ]^  
-UMPt"o  
6. HLA class II antigen @8jc|X<A  
D#pZN,'  
7. complementarity-determining region (CDR) 2GB+st,  
ee7{5  
8. perforin(or pore-forming protein ,PFP) B4>kx#LR  
KXtc4wra  
9. high affinity IL-2 receptor )= :gO`"D  
_Cd_i[K[  
10. artificial active immunization ,]\:]Y&?  
&M5_G$5n  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© i]L4kh5  
|fd}B5!c  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠxwm-)~L4T  
L 2Z9g`>  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 +~H mP Q  
Z#i5=,Bk  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ dl %KD8  
kV mJG#  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ ] SErM#$*  
potb6jc?  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ ;44?`[oP  
b O:m^*  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? ti)4J2c,8  
%L^S;v3  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ o (OC3  
7T)J{:+0!|  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ .-0;:>  
-c1$>+  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ DJF-J#  
'za4c4b*u  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ 'aWzam>  
A^a9,T  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© W9$mgs=S`E  
m9Z3q ;  
1. immunoglobulin gene rearrangement TAbC-T.EV  
rdL>yT/A  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) Dyx3N5?C  
u/D=&"tL  
3. flow cytometry(FCM) f"0{e9 O]2  
#\&jM -.-  
4. carrier effect ={a8=E!;  
9tnW:Nw~  
5. positive selection of T lymphocytes in thymus Y^?J3[@  
@jE<V=?  
6. mouse TH1(Th1) and TH2(Th2) subsets R ks3L  
]0HlPP:2  
7. perforin (pore-forming protein ,PFP) [-@Lbu-|  
$=j}JX}z  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) Hm?zMyO.k  
T/^ /U6JB  
9. SH-2(src-homology region 2) &&  }'  
T[iwP~l  
10. Ab2¦Â (internal image) ;b[% L&  
(~r"N?`  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© uC>X;<^   
Ksq{=q-T  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? Z[baQO  
N U*6MT4  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? 0 R,?$qM\  
+h6c Aqm]  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠi; 1aobG  
Q0f7gY1-%  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ -E4e8'P;5  
@)>9l&  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠqV$\.T>x  
-.|V S|y  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) _5vAn t*  
[N}:Di,S  
ÃâÒßѧרҵ£º [YY[E 7  
SU.T0>w  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ %aU4d e^  
x8Rmap@L.  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? 1!"0fZh9U  
K@P5]}'#  
´«È¾²¡Ñ§×¨Òµ£º [kx_Izi/T  
gaaW:**y  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ ZPWY0&9  
LlP_`fA  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ ,[}5@cS  
%EYh5 W  
Ïû»¯×¨Òµ£º " d3pkY  
SF2A?L?}+  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£  $9dm2#0d  
$\l7aA5~  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? 6LRI~*F=3  
;aKdRhDo  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ h V@C|*A  
{dV#"+  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ?y82S*sb#  
3!M;Z7qF]  
1. Fas(CD95)/FasL E(A7DXzbR  
<>`+" O}  
2. common chain of cytokine receptor 2Q`@lTUv  
Bi9 b"*LN  
3 . TCR/CD3 complex W8j)2nKD  
Hzs]\%"  
4. negaive selection of thymocytes  *r Y6  
^~Nz8PCY  
5. artificial active immune deSrs:.  
bj4cW\b(  
6. anti-idiotypic 8FyJo.vr(  
VyH'7_aU  
7. IgSF ^OKCvdS  
xg %EQ  
8. Integrin `2\vDy1,j  
zRPX mu{t  
9. chemokine <@xp. Y  
v;" [1w}  
10. B7/CD28 I=X-e#HM?  
n5 dFp%k  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©  $wUFHEl  
Q{6Bhx *>  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ :RR<-N5+  
'F3Xb  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ }N^.4HOS8  
_2+}_ >d  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ $A\fm`  
$6.CN#  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ @ qWgokf  
pMM,ox"  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ $}&Y$w>S  
L A-H  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ 9 lE[oAC  
(&R /ns~  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© g*69TqO^  
B}_*0D  
1. B7/CD28 yi*)g0M  
O@r%G0Jge  
2. Th1 subset >aXyi3B  
c}GmS@  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© heJI5t,  
$,$bZV  
4. antibody affinity maturation 7Y T%.ID  
- y[nMEE  
5. AP-1 -Yx'qz@  
6Mu_9UAl`  
6. single chain variable fragment£¨ScFv£© DX u915  
vw VeHjR  
7. NK cell receptor 1y@d`k`t:  
("-Co,4ey  
8. Zinkernagel-Doherty phenomenon A\p' \@f  
) =-$>75Z  
9. Ig fold $SAq/VHI1]  
_b8&$\>  
10. CD40/CD40L ZDEz&{3U;  
J%ng8v5ex  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© ap hfzo  
j"6r]nc&  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ l~P%mVC3m  
3cfJ(%'X  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ ~ 8L]!OQ9=  
k4:$LFw@  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ `-@8IZ7  
+KV?W+g)`  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ }e$^v*16  
}j<:hD QP  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ '}#=I 9=ss  
8@;|x2=y  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ B(tLV9B3Q  
%oPW`r  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ 0u[Vd:()v(  
<Y%km[Mh  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© 7{jB!Xj  
Fg` P@hC  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© 0 D^d-R,  
+xoh=m  
1.Co-stimulators (or co-stimulating molecules) Fuq MT`  
a,eR'L<"*-  
2.NK-kB x=-dv8N?  
scr`] tD  
3.Immunoglobulin superfamily %3p~5jhm1  
\ a}6NIo  
4.antigen-presenting cell (APC) $z1W0  
;MSdTHN"  
5.death domain \iN3/J4  
&Bn> YFu  
6.CCR and CXCR Ltk'`  
v67utISNI  
7.Lectin (or mitogen) op!ft/Yyb  
C1V :_-  
8.Clusters of differentiation, CD) gc5u@ (P"  
I`e$U  
9.B7 family VIIBw  
<H; z4  
10.Cytotoxic T lymphocyte, CTL) i sK_t*  
yM_ta '^$  
11.IL-15 and IL-15 receptor (IL-15R) U3UKu/Z  
30BFwNE  
12.MHC restriction jRn5)u  
N*^iOm]Y  
13.Affinity-chromatography <^+x}KV I  
SRP.Mqg9  
14.Cyctosprin A, CsA 1\t#*N  
1')_^]  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC)  }q$6^y  
6np  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© MbT;]Bo  
MBIlt 1P  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 5YV3pFz$)  
o[A y2"e?  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ s^&Oh*SP*  
{s{ b nU  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ /W|=Or2oR  
w'r?)WW$  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 1H-d<G0)  
;h"St0   
ÃâÒßѧרҵ£º )%zOq:{\5  
u4KP;_,m  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ TXWYQ~]3w  
/0_^Z2  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 5R%4fzr&g  
wCitQ0?  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ \*+-Bm:$j  
'JpCS  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) 0XzrzT"&  
uD0<|At/  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) } \?]uNH  
~Qm<w3oy  
1. ADCC(antibody dependent cell-mediated cytotoxicity) dR GgiQO  
$&ZN%o3  
2. »·æß¾úËØ(cyclosporin) n# 4e1n+I  
6>d0i S@R  
3. KIR(killer cell inhibitory receptor) S2\|bs7;J,  
*RllKPY)  
4. HLDA(human leucocyte differentiation antigen) KmX?W/%R  
XIRvIwO  
5. Interleukin 18(IL-18) JW2~ G!@  
!?aL_{7J  
6. ÕûºÏËØ(integrin) wgcKeTD9  
@\?QZX(H  
7. Fas/FasL qZB}}pM#  
*t_JR  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) =C4!h'hz  
XdV(=PS!a@  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) ^77X?nDz=h  
@3Nvf}He  
10. Th1/Th2 nJr:U2d  
e .(  
11. »ùÒòÒßÃç(DNAÒßÃç) "yG*Kh7ur  
zcCGR Ee=  
12. chemokines and chemokine receptor }pOJM &I  
RA ER\9i  
13. ÃâÒßÄÍÊÜ 3aERfIJyE  
lEr_4!h$rZ  
14. ¹²´Ì¼¤·Ö×Ó )9~-^V0A^>  
"]kq,j^]  
15. ËÀÍö½á¹¹Óò(death domain) Cp!Qd e  
`CqF&b  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) $ (N+E,XB  
~7O.}RP0  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? )^[PW&=W|x  
~(Xzm  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠhw)#TEt   
-XMWN$Ah  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î / PTk296@  
XFJz\'{  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ 9 6j*F,{  
h:~ 8WV|  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå ]h 4r@L3  
&!0%"4  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ vi~NfD@s  
"S^ ""5  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) Rw]lW;EN<  
`71(wf1q[f  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ iVAAGZ>am  
(GB*+@  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ \ ix& U  
gf^XqTLs  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»